Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Top Page
Aligos Therapeutics
(NASDAQ:ALGS)
Select Model
Select Model
Rating:42Neutral
Price Target:
$7.50
▼(-5.90% Downside)
Action:ReiteratedDate:03/06/26
The score is mainly held down by very weak financial performance (zero revenue in 2025, persistent losses, and heavy cash burn) and a bearish technical setup (below key moving averages with negative MACD). Valuation offers limited support due to ongoing losses and no dividend, while the leadership/accounting appointment is a modest positive but not enough to offset the core fundamentals.
Positive Factors
Focused clinical-stage pipeline (HBV, NASH)
Aligos’s concentrated R&D focus on HBV and NASH represents a durable strategic advantage: specialization can improve trial design, target validation, and partner appeal in high unmet-need markets. Over 2–6 months this supports potential partnership/licensing optionality and clearer resource allocation.
Negative Factors
Revenue collapsed to $0 in 2025
Zero reported revenue in 2025 underscores that Aligos remains wholly pre-commercial; lacking product sales, the firm must rely on external capital or milestone payments. This structural absence of internal revenue generation increases financing and execution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical-stage pipeline (HBV, NASH)
Aligos’s concentrated R&D focus on HBV and NASH represents a durable strategic advantage: specialization can improve trial design, target validation, and partner appeal in high unmet-need markets. Over 2–6 months this supports potential partnership/licensing optionality and clearer resource allocation.
Read all positive factors
Aligos Therapeutics (ALGS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$49.32M
Dividend YieldN/A
Average Volume (3M)86.97K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-55.88%
EPS Growth6.14%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.91
Shares Outstanding5,387,807
10 Day Avg. Volume122,947
30 Day Avg. Volume86,969
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue16.54
Enterprise Value/Gross Profit21.65
Enterprise Value/Ebitda-0.42
Forecast
1Y Price Target
$39.33Price Target Upside393.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.47
Revenue Forecast (FY)$1.70M
Aligos Therapeutics Business Overview & Revenue Model
Company Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligon...
How the Company Makes Money
null...
Aligos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.19M | 3.94M | 15.53M | 13.91M | 4.36M |
| Gross Profit | 1.26M | 3.94M | 15.53M | 13.91M | 4.36M |
| EBITDA | -87.06M | -86.53M | -85.06M | -93.91M | -124.54M |
| Net Income | -24.19M | -131.21M | -87.68M | -96.05M | -128.33M |
Balance Sheet | |||||
| Total Assets | 88.53M | 70.09M | 151.53M | 146.69M | 235.37M |
| Cash, Cash Equivalents and Short-Term Investments | 77.84M | 56.94M | 135.70M | 125.83M | 190.73M |
| Total Debt | 5.25M | 8.38M | 11.14M | 12.57M | 14.46M |
| Total Liabilities | 34.99M | 99.07M | 59.45M | 42.79M | 50.64M |
| Stockholders Equity | 53.55M | -28.97M | 92.08M | 103.90M | 184.73M |
Cash Flow | |||||
| Free Cash Flow | -82.94M | -80.87M | -79.02M | -80.33M | -116.55M |
| Operating Cash Flow | -82.50M | -80.74M | -79.00M | -79.39M | -115.66M |
| Investing Cash Flow | -37.83M | -18.28M | 44.98M | -26.29M | 3.02M |
| Financing Cash Flow | 101.64M | 355.00K | 88.33M | 164.00K | 78.68M |
Aligos Therapeutics Technical Analysis
Positive
7.97
Price Trends
7.28
Positive
8.29
Negative
8.68
Negative
Market Momentum
0.03
Negative
60.13
Neutral
90.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Positive. The current price of 7.97 is above the 20-day moving average (MA) of 7.19, above the 50-day MA of 7.28, and below the 200-day MA of 8.68, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 60.13 is Neutral, neither overbought nor oversold. The STOCH value of 90.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALGS.
Aligos Therapeutics Risk Analysis
Aligos Therapeutics disclosed 93 risk factors in its most recent earnings report. Aligos Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aligos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $58.89M | -1.19 | -53.71% | ― | ― | 21.17% | |
44 Neutral | $38.35M | -0.59 | 763.31% | ― | -15.81% | -113.06% | |
44 Neutral | $24.51M | -0.43 | -70.57% | ― | -100.00% | -26.30% | |
42 Neutral | $49.32M | -3.81 | -28.16% | ― | -55.88% | 6.14% |
* Healthcare Sector Average
ALGS
Aligos Therapeutics
7.97
2.92
57.82%
MNOV
Medicinova
1.44
0.24
20.00%
CELU
Celularity
1.33
-0.06
-4.32%
BRNS
Barinthus Biotherapeutics
0.60
-0.08
-11.76%
GNTA
Genenta Science SpA Sponsored ADR
0.71
-2.78
-79.66%
ACRV
Acrivon Therapeutics, Inc.
1.52
0.13
9.35%
Aligos Therapeutics Corporate Events
Executive/Board Changes
Aligos Therapeutics Appoints New Principal Accounting Officer
Positive
Feb 4, 2026
On January 29, 2026, Aligos Therapeutics, Inc. appointed Nikhil Aneja as its Principal Accounting Officer, succeeding Lesley Ann Calhoun in that specific role while she continues as Executive Vice President, Chief Operating Officer and Chief Finan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.